MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Simulations Plus Inc

Geschlossen

BrancheGesundheitswesen

23.58 -4.92

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

22.95

Max

23.81

Schlüsselkennzahlen

By Trading Economics

Einkommen

-637K

206K

Verkäufe

260K

19M

KGV

Branchendurchschnitt

61.3

63.778

EPS

0.17

Dividendenrendite

0.99

Gewinnspanne

1.089

Angestellte

243

EBITDA

-929K

126K

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+104.56% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.99%

2.39%

Nächstes Ergebnis

1. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

493M

Vorheriger Eröffnungskurs

28.5

Vorheriger Schlusskurs

23.58

Nachrichtenstimmung

By Acuity

45%

55%

152 / 386 Ranking in Healthcare

Simulations Plus Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Juli 2024, 08:59 UTC

Top News

These Stocks Are Moving the Most Today: Tesla, Paramount, Nvidia, Constellation Brands, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Simulations Plus Inc Prognose

Kursziel

By TipRanks

104.56% Vorteil

12-Monats-Prognose

Durchschnitt 50.67 USD  104.56%

Hoch 65 USD

Tief 37 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Simulations Plus Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

4

Buy

1

Halten

0

Sell

Stimmung

By Acuity

152 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.